Cargando…
COVID-19-related autoimmune disorders of central nervous system (CRAD-C): Is it a new entity?
Autor principal: | Naser Moghadasi, Abdorreza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253721/ https://www.ncbi.nlm.nih.gov/pubmed/34229045 http://dx.doi.org/10.1016/j.autrev.2021.102888 |
Ejemplares similares
-
Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer
por: Ashshi, Ahmad Mohammad, et al.
Publicado: (2016) -
Importance of T-cell response to COVID-19 vaccination in patients with multiple sclerosis treated by anti-CD20 therapies: New vaccines are required to be developed
por: Naser Moghadasi, Abdorreza
Publicado: (2021) -
Eculizumab in the treatment of neuromyelitis optica spectrum disorder
por: Nabizadeh, Fardin, et al.
Publicado: (2023) -
Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors
por: Xia, Xi, et al.
Publicado: (2011) -
Encephalopathy associated with COVID-19 in a patient with multiple sclerosis
por: Naser Moghadasi, Abdorreza
Publicado: (2020)